Contact Genzyme

1-877-4MOZOBIL (1-877-466-9624)

If you would like to contact Genzyme Medical Information with questions about Mozobil, please fill in the fields below (required fields are marked with an asterisk) and click "submit." The information you provide will be maintained in accordance with our privacy policy. For more information about Genzyme's privacy policy, please click on the link at the bottom of this page. Unfortunately, Genzyme cannot accept medical questions that contain personal medical information.

All fields marked with * are required.

Please correct the information marked in red.

* First name

* Last name

* Street Address

Street Address 2

* City

* State

* Zip Code

Daytime Telephone

* Email address

* Confirm email address

Preferred method of contact
email
telephone

* Comment or question

Questions to Ask Your Doctor

Have concerns but don’t know where to begin? Read, download and print our list of questions to ask your doctor.

Prepare for an Autologous Stem Cell Transplant

Learn more about the autologous stem cell transplant process and what to expect with our easy-to-follow step-by-step guide.

Download guide (PDF)

Indication

Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).

Important Safety Information

Mozobil is not intended for HSCT mobilization and collection in patients with leukemia.
Mozobil in combination with G-CSF increases circulating WBCs. Your WBC counts will be monitored.
Thrombocytopenia (a decrease in the number of platelets circulating in the blood) has been observed in patients receiving Mozobil. Your platelet counts will be monitored.
Cancer cells may be released from the bone marrow and subsequently collected along with your stem cells during apheresis. The potential effects of infusing cancer cells during your transplant have not been well-studied.
Your spleen may be examined if you experience pain in the left upper stomach area or left shoulder area as these may be signs of an enlarged or burst (ruptured) spleen.
Mozobil may harm the unborn child when administered to a pregnant woman. Scientific studies have shown that Mozobil caused harm to unborn animals. The safety of Mozobil in pregnant women has not been established in clinical trials. If you are of childbearing potential you should be advised to avoid becoming pregnant while receiving treatment with Mozobil. If this drug is used during pregnancy, or if you become pregnant while taking this drug, you should be apprised of the potential hazard to the unborn child.
The most common adverse reactions (occurring in greater than or equal to 10% of patients) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), tiredness (fatigue) (27%), injection site reaction (34%), headache (22%), pain in your joints (arthralgia) (13%), dizziness (11%), and vomiting (10%).